Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Open Access
- 18 July 2023
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 30 (7) , 6805-6819
Abstract
Over the past few decades, immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic options for the treatment of various cancers. These novel treatments effectively target key mediators of immune checkpoint pathways. Currently, ICIs primarily consist of monoclonal antibodies that specifically block cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and lymphocyte activation gene 3 protein (LAG-3). Despite the notable efficacy of ICIs in cancer treatment, they can also trigger immune-related adverse events (irAEs), which present as autoimmune-like or inflammatory conditions. IrAEs have the potential to affect multiple organ systems, with cutaneous toxicities being the most commonly observed. Although cutaneous irAEs are typically of low-grade severity and can usually be managed effectively, there are cases where severe irAEs can become life-threatening. Therefore, early recognition and a comprehensive understanding of the mechanisms underlying cutaneous irAEs are crucial for improving clinical outcomes in cancer patients. However, the precise pathogenesis of cutaneous irAEs remains unclear. This review focuses on the skin manifestations induced by ICIs, the prognosis related to cutaneous irAEs, and the exploration of potential mechanisms involved in cutaneous irAEs.Keywords
Funding Information
- Taiwan National Science and Technology Council (MOST-110-2628-B-037-007, NSTC-111-2314-B-037-042, KMUH110-0R61, KMUH111-1R59)
- Kaohsiung Medical University Hospital (MOST-110-2628-B-037-007, NSTC-111-2314-B-037-042, KMUH110-0R61, KMUH111-1R59)
This publication has 126 references indexed in Scilit:
- Drug Hypersensitivity Reactions: Pathomechanism and Clinical SymptomsMedical Clinics of North America, 2010
- Autoantibodies against desmocollins in European patients with pemphigusClinical and Experimental Dermatology, 2009
- CTLA-4 Control over Foxp3 + Regulatory T Cell FunctionScience, 2008
- Galectin-3: An open-ended storyBiochimica et Biophysica Acta (BBA) - General Subjects, 2006
- Mechanismen kutaner arzneimittelinduzierter ReaktionenJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2004
- Characterization of a Novel C-type Lectin-like Gene, LSECtinJournal of Biological Chemistry, 2004
- Immunohistology of drug-induced exanthema: clues to pathogenesisCurrent Opinion in Allergy and Clinical Immunology, 2001
- Immunohistology of drug-induced exanthema: clues to pathogenesisCurrent Opinion in Allergy and Clinical Immunology, 2001
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.Journal of Experimental Medicine, 1992